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Abstract: Extracorporeal membrane oxygenation (ECMO) is associated with frequent hemorrhagic
and thromboembolic complications. The multiple effects of ECMO include inflammatory response on
contact with the circuit; hemolysis acquired von Willebrand syndrome likely affects the function of
red blood cells (RBC) and platelets. The aim of this prospective observational study was to analyze
RBC aggregation and elongation (deformability) and platelet aggregation in the first week of ECMO.
Sixteen patients were included. Blood samples were taken prior to initiation of ECMO and on days
1, 2, 3, 5, and 7. RBC aggregation and elongation were analyzed using the laser-assisted optical
rotational red cell analyzer (Lorrca). Upstroke, top, and amplitude as indices of aggregation showed
significant time effects. RBC elongation was not affected at low shear stress. At high shear stress
there was an increase in the elongation index at day 2 (p = 0.004), followed by a decrease. Platelet
function was analyzed using multiple electrode aggregometry (Multiplate®). In pairwise comparison
in the days 1–7 to the value prior to ECMO there was no significant difference in platelet aggregation
by any of the three agonists (ADP p = 0.61; TRAP p = 0.77; Ristocetin p = 0.25). This implies that the
rheology of RBCs seemed to be more affected by ECMO than platelets. Especially the red blood cell
deformability continues to decline at higher shear stress.
Keywords: extracorporeal membrane oxygenation; bleeding; platelet function
1. Introduction
Extracorporeal membrane oxygenation (ECMO) is increasingly used in the intensive care unit
(ICU) and has improved the survival of patients with critical respiratory and/or circulatory failure.
However, complications of ECMO treatment are frequent. Especially the incidence of hemorrhage
(15%–20%) and to a lesser extent thromboembolic events (2%–4%) during ECMO treatment are
significant [1]. This may in part be caused by the effect of ECMO on the function of red blood cells and
platelets. Exposure of blood to the surface of the ECMO circuit initiates the contact factor pathway,
activates platelets, and induces an inflammatory response. As a consequence, hemostasis is disrupted,
coagulation is promoted, and in the absence of anticoagulation, a thrombus may form, resulting in
device failure or embolic stroke. Anemia is also frequent during ECMO treatment due to (postoperative)
blood loss or hemolysis. Hemolysis as an expression of membrane instability may be preceded by
changes in aggregation and deformability of the red blood cells (RBCs) [2]. Such changes may also
J. Clin. Med. 2020, 9, 1168; doi:10.3390/jcm9041168 www.mdpi.com/journal/jcm
J. Clin. Med. 2020, 9, 1168 2 of 11
affect the ability of RBCs to interact in normal coagulation and thus result in hemorrhage. On the
contrary, free hemoglobin was found to promote platelet adhesion and formation of micro thrombi
on Von Willebrand factor, indicating that free hemoglobin is associated with thrombotic events [3].
Alterations in RBC rheology (reduced deformability and increased aggregation) were demonstrated in
a prospective study in septic patients and reductions in RBC deformability over time are associated
with a poor outcome [4]. It is therefore necessary to analyze both platelet function and RBC properties
during ECMO. The extreme deformability of RBCs plays a role in the microcirculation. RBCs can pass
through capillaries with a diameter of approximately half the diameter of the RBC in rest. This property
is also responsible for the surprisingly low viscosity at high shear rates in the large arteries under
normal circumstances when RBCs take up almost 50% of the volume of whole blood. It can therefore
be expected that even small increases in RBC rigidity might lead to significant disturbances in the
microcirculation [5]. Poor microcirculation at initiation of veno-arterial (VA) ECMO and the inability to
restore the microcirculation during the first 24 h is associated with mortality [6,7]. Thrombocytopenia
in patients on ECMO is frequent but the severity of the underlying illness and platelet count at the
time of ECMO cannulation seem to be more important risk factors for bleeding [8]. Acquired von
Willebrand syndrome and impaired platelet function is also described during VV ECMO support and
may be more associated with hemorrhagic complications than the absolute platelet count [9,10].
Insight into the interaction between red blood cells, platelets and vascular wall may help to
prevent these bleeding complications and to decrease thrombotic events. Therefore, it is likely that
ECMO therapy affects both RBC and platelet function after its initiation, however, the time course
of these changes and their clinical relevance is yet unclear. We hypothesized that RBC rheology and
platelet function changes over time after the start of ECMO. The aim of the current study was to
analyze RBC function, measured by aggregation and elongation (deformability) and platelet function
measured by aggregation in the first week of ECMO.
2. Experimental Section
2.1. Trial Design and Patients
We conducted a single center prospective observational study at University Medical Center
Groningen, the Netherlands, functioning as an ECMO referral center. The study was approved by the
Medical Ethical board (METc 2017/550). Written informed consent was obtained.
2.2. Study Population
Inclusion criteria were patients aged 18 years or older requiring ECMO. Exclusion criteria were
subsequent start of VA ECMO after the use of cardiopulmonary bypass (unless there was a measurement
done prior to the procedure as baseline), pregnancy and use of ECMO only for support during high
risk procedure like percutaneous cardiac intervention with planned removal of ECMO within 24 h.
2.3. ECMO Management
ECMO was provided with a Cardiohelp® system (Maquet Critical Care, Solna, Sweden) equipped
with a HLS Set Advanced 7.0 with a biocompatible BIOLINE Coating (Maquet). Unfractionated
heparin (heparin Leo®, Ballerup, Denmark) was used for anticoagulation with a target activated partial
thromboplastin time between 50 and 70 s.
2.4. Blood Sampling
A baseline blood sample was obtained from the arterial line prior to ECMO initiation. Additional
samples were collected the next day (day 1) and at days 2, 3, 5, and 7, if the patients were still receiving
ECMO support. Samples were taken from the arterial line and anticoagulated in 3 mL hirudin tubes
(Roche, Basel, Switzerland).
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2.5. Laser-Assisted Optical Rotational Red Cell Analyzer
Both RBC aggregation and deformability as determinants of the blood viscosity were
determined by a laser-assisted optical rotational red cell analyzer (Lorrca, RR Mechatronics,
Hoorn, The Netherlands) [11]. The blood samples were measured without hematocrit correction.
During measurement, each sample was sheared under rotation at 37 ◦C in a concentric-cylinder
system with a gap of 0.3 mm between the cylinders. A syllectogram was created by plotting the
laser backscattered intensity, measured by a photodiode, versus time (Figure 1). The reflection was
measured over a period of 120 s at a rate of 100 samples per second. First, complete disaggregation of
the RBCs was induced by applying a high shear rate. This is reflected in the initial laser backscattered
intensity (Figure 1). An abrupt stop of the motor caused the elongated and orientated RBCs to retake
their normal, biconcave, shape and orientate randomly. This is reflected in the upstroke, and then the
aggregation process starts, at which point RBCs form large stacks (rouleaux) reflected in the amplitude.
The amplitude may be combined with the time to obtain a single number: the aggregation index (AI).
For the measurement of RBC deformability, the RBCs are elongated under various shear rates that lead
to shear stresses from 0 to 49.84 Pa. The elongation index (EI) is used to estimate the ability of RBC
deformation by calculating the ratio of long and short axes of the deformed RBCs at the preset shear
rates. We present data for a low (0.57 Pa) and a high (7.49 Pa) shear stress.
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Figure 1. Syllectogram of red blood cell (RBC) aggregation: The intensity of laser backscatter (Isc)
plotted versus time before and after a sudden stop of the motor. RBC morphology, corresponding to
the various parts of the curve, is indicated (see text).
2.6. Multiple Electrode Aggregometry
Platelet function analysis was performed with the Multiplate® Analyzer (Roche Diagnostics
International Ltd., Munchen, Germany). This system measures impedance changes as platelets
aggregate between two double-sensor electrodes immersed in a cuvette. The increase in impedance is
transformed into aggregation units (AU) and plotted against time on the computer screen. Hirudin
anticoagulated whole blood rested for a maximum of 30 min before analysis. Whole blood was diluted
with isotonic saline 1:1 followed by three minutes of incubation at 37 ◦C. The platelet aggregation
response was studied with adenosine diphosphate (ADP, 6.4 µM), a direct platelet activator, with
thrombin receptor activating peptide (TRAP, 32 µM), a strong direct activator to assess the maximal
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activation response, and with high dose ristocetin (Risto, 50 µL, 0.77 mg/mL), an indirect activator
which induces von Willebrand factor mediated platelet activation, which might be more affected
by ECMO.
2.7. Statistics
Since there were no data available for the effects of ECMO on Lorrca, no formal sample size
calculation was performed for this explorative analysis. Categorical variables are reported as frequencies
and percentages. Normally distributed data are described as mean ± standard deviation. Not normally
distributed data are presented as median with interquartile range (IQR). For comparisons we used
the Mann–Whitney test. As we had missing values, for example due to early ECLS withdrawal,
we used for the repeated measurement analysis a parsimonious linear mixed model based on Aikake’s
information criterion with time as fixed effect and compound symmetry as covariate structure




We studied 16 consecutive patients treated with ECMO in our ICU between July 2018 and August
2019. Patient’s demographics are presented in Table 1. The hemoglobin concentrations fell from
6.7 ± 1.6 mmol/L just before initiation of ECMO to 5.4 ± 1.0 mmol/L on the first day and stabilized
thereafter on 4.4 ± 0.5 mmol/L. Platelet count just prior to initiation of ECMO was 223 ± 101 × 109/L
which decreased to 187 ± 103 on day 1. D-dimers increased from 6795 ± 12,878 µg/L at day 1 of ECMO
to 22,129 ± 25,901 µg/L at day 7. The number of patients who received transfusion of blood products is
shown in Figure 2.
Table 1. Patient characteristics at baseline.
Patients (n) 16
Age, mean 50 ± 12
Gender, male 10 (63%)
Body mass index (kg/m2), mean 26 ± 4





APACHE IV score, mean 101 ± 35
Duration of ECMO, days median (IQR) 5.5 (2.25–14.5)
Successful weaning of ECMO 7 (44%)
Hemoglobin, prior to start ECMO, mean 6.7 ± 1.6 mmol/L
Platelets, prior to start ECMO, mean 223 ± 101 × 109/L
D-dimers, on the first day of ECMO, mean 6795 ± 12,878 µg/L
Fibrinogen, on the first day of ECMO, mean 4.4 ± 2.7 g/L
ECMO: extracorporeal membrane oxygenation; VA: veno-arterial; ECPR: extracorporeal life support; APACHE: acute
physiology and chronic health evaluation.
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Figure 2. Transfusion of blo d products. Horizontal axis shows days on extracorporeal membrane
oxygenation (ECMO). Vertical axis shows number of patients transfused. The numbers in the upper
part of the graph depict the patients on ECMO on that day.
3.2. Laser-Assisted Optical Rotational Red Cell Analyzer
3.2.1. Red Blood Cell Aggregation
There were significant time effects for the initial scatter intensity (p = 0.003), the top of the laser
backscatter intensity (p = 0.001), the upstroke (p = 0.001), and the amplitude which is the total extent
of the aggregation (p = 0.015) in Figure 3. All these parameters are part of RBC aggregation, which
combined with the time may be calculated and result in the AI. This calculated index showed a trend
towards decrease in the first week on ECMO, but this time-effect was not significant (p = 0.110).
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3.2.2. Red Blood Cell Deformability
After a small increase with a maximum on day 2 there was a slight decrease in EI. At all time points
the measurements showed alteration in RBC deformability (Figure 4). The EI reached a maximum of
0.3 and decreased at a shear stress of 7.34 Pa. In a pairwise comparison to the value prior to ECMO
there was no significant difference in the values of the elongation index in the days 1 through 7 at low
shear stress. Although there was a significant time effect (p = 0.041) in univariate testing. In a pairwise
comparison to the value prior to ECMO there was a significant difference in the value of the elongation
index at day 2 (p = 0.004) at high shear stress. There was also a significant time effect (p = 0.004) in
univariate testing.
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3.3. Platelet Function Analysis with Multiplate
In Figure 5 the results of the platelet function analysis are presented. The median value of ADP
prior to ECMO was 43 AU (IQR 19–71), below the reference range (53–122 AU). For TRAP the median
value prior to ECMO was 99 AU (IQR 60–129), within the reference range (94–156 AU). For the indirect
activator Ristocetin, the median value prior to ECMO was far below the reference range of 90–201 AU,
with 34 AU (IQR 20–99). In pairwise comparison in the days 1–7 to the value prior to ECMO there
was no significant difference in platelet aggregation by any of the three agonists (ADP p = 0.61; TRAP
p = 0.77; Ristocetin p = 0.25).
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dots represent the outliers. ECLS = extracorporeal life support.
4. Discussion
The most important finding of our study is that the rheology of red blood cells seems to be more
affected by ECMO than platelet function. Especially the red blood cell deformability continues to
decline at higher shear stress, however, the effect seems minor.
To gain more insight into the interaction of ECMO and RBCs, we focused on the components
that form the syllectogram, more than the composed AI. The AI did not significantly alter over time,
but all components that make up the AI did. The basic laser scatter intensity, the upstroke, and the
amplitude all significantly decreased over the time points. The decrease in upstroke points towards
less disaggregation into single RBCs while the amplitude which is the total extent of the aggregation
points to less forming of rouleaux during ECMO. Both findings suggest that the membrane properties
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of the RBCs are affected by ECMO. However, and this is a limitation of our study, hemoglobin levels
also decreased during ECMO treatment and there may be a causal relationship with the lowering of the
basic laser scatter intensity, upstroke and hematocrit levels. Hardeman reported that the total extent of
RBC aggregation as measured with the Lorrca, was found to be nonlinear dependent on hematocrit
with an optimum between 0.42 and 0.46 L/L, in line with the findings of Deng et al., obtained with light
transmission technology [11]. The AI increased steadily over the hematocrit range 0.18 to 0.78 L/L [12].
We consider this a less likely explanation for our findings as our hemoglobin levels remained in a
reasonably narrow and clinically acceptable range.
One of the stronger points of our study is that aggregation and deformation of RBCs in ECMO
patients has not been studied before. In patients undergoing cardiac surgery with the use of
cardiopulmonary bypass the use of mechanical cell saver did not alter the AI but led to a significantly
lower EI, meaning that the mechanical cell saver seemed to add additional shear stress and led to
decreased deformability [13]. Combined with our results this suggests that mechanical treatment
of blood affects the membrane properties, but our study does not allow us to assess the degree of
microcirculatory impairment.
Using an ektacytometer, it was shown that cardiac surgery with cardiopulmonary bypass is
associated with a dose-dependent decrease in RBC deformability when stored allogeneic RBCs were
transfused; this effect was not seen with autologous salvaged RBCs [14]. A number of our patients
also received allogeneic transfusions and this may have affected our results. However, it would be
unethical to withhold the blood transfusions given our restrictive transfusion policy. Given our small
cohort we did not perform a separate analysis of transfused and nontransfused patients.
In the sepsis study using the Lorrca, the AI in septic patients was higher than in healthy volunteers
and nonseptic ICU patients. RBC deformability was already reduced in septic patients at ICU admission
and worsened in nonsurvivors. In nonseptic patients these changes were not observed [4]. This effect
in aggregation might be related to higher fibrinogen levels in sepsis patients as fibrinogen is needed to
form bridges between the RBCs and facilitate aggregation but this was not shown. In our patients
the AI showed a trend towards lowering on ECMO while the fibrinogen levels remained stable.
The deformability is reduced as shown in the relatively low maximum of the elongation index and
the significant time effect at high(er) shear stress. This might have a detrimental impact on the
microcirculation. We did not find a time-effect for platelet function during ECMO with the multiplate
suggesting a functional balance in the light of developing (mild) thrombocytopenia. This effect was
also seen in a study in twenty patients on VV ECMO where platelet function was impaired prior to
the ECMO initiation; ECMO led to a further impairment but after two days the values recovered to
baseline [15]. In a study with both VV and VA ECMO patients it was shown that the platelet aggregation
was not impaired when the results were interpreted considering the low platelet counts [16].
Studies on ECMO patients are limited in interpretation due to the heterogeneous population with
a variety of underlying illness leading to the need for ECMO support. The results of the present study
are confounded by blood loss and transfusions of RBCs, plasma, and platelets. Multiplate might not be
the most appropriate analyzer for platelet dysfunction on ECMO. Most studies, including ours, are
influenced by developing thrombocytopenia during ECMO. The extent of the influence of hemoglobin
oxygenation grade on the results of the Lorrca is not exactly known but probably negligible [5].
5. Conclusions
Although ECMO caused only minor changes in RBC properties, there was a trend towards
a reduced deformability and aggregation of the red blood cells over time during extracorporeal
membrane oxygenation. This time dependent effect was not seen in platelets.
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